中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 11
Nov.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(11): 2441-2445

Association of interleukin-2 receptor expression with liver pathological changes in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2020.11.009

  • Department of Gastroenterology,Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Research funding:

 

  • Received Date: 2020-05-15
  • Published Date: 2020-11-20
    Abstract

  • Objective To investigate the association between serum interleukin( IL) and liver pathological changes in patients with chronic hepatitis B( CHB). Methods A total of 59 patients with CHB who were treated in Putuo District Central Hospital of Shanghai from February 2018 to February 2019 were enrolled as subjects,and liver biopsy was performed for all patients. According to the degree of liver inflammation,the patients were divided into mild inflammation( G1-G2) group and severe inflammation( G3-G4) group,and according to the degree of liver fibrosis,the patients were divided into mild fibrosis( S0-S2) group and severe fibrosis( S3-S4) group. Serum liver function parameters,blood lipids,interleukin-2( IL-2),interleukin-6( IL-6),interleukin-8( IL-8),and interleukin-10( IL-10)were measured for all patients. The independent samples t-test was used for comparison of normally distributed continuous data between two groups,and the Wilcoxon non-parametric test was used for comparison of non-normally distributed continuous data between two groups;the chi-square test was used for comparison of categorical data between groups. A Spearman correlation analysis was also performed.Results The degree of liver fibrosis increased with the increase in liver inflammation( rs= 0. 538,P < 0. 001). Compared with the mild inflammation group,the severe inflammation group had significantly higher serum levels of alanine aminotransferase [95. 00( 45. 00-169. 25) U/L vs 51. 00( 29. 00-88. 00) U/L,Z =-2. 625,P = 0. 009],aspartate aminotransferase [54. 50( 34. 75-84. 50) U/L vs38. 00( 30. 00-49. 00) U/L,Z =-2. 014,P = 0. 044],and gamma-glutamyl transpeptidase [91. 00( 56. 72-192. 25) U/L vs 44. 00( 24. 00-100. 00) U/L,Z =-2. 400,P = 0. 016]. The severe fibrosis group had a significantly higher serum level of high-density lipoprotein than the mild fibrosis group [0. 97( 0. 32-1. 08) mmol/L vs 1. 23( 0. 36-1. 38) mmol/L,Z =-1. 300,P = 0. 008]. The severe inflammation group had a significantly higher serum level of IL-2 receptor than the mild inflammation group [704. 00( 418. 00-1038. 00) U/ml vs 436. 00( 335. 00-555. 00) U/ml,Z =-3. 405,P = 0. 001],and the severe fibrosis group had a significantly higher serum level of IL-2 receptor than the mild fibrosis group [735. 00( 523. 00-890. 50) U/ml vs 447. 00( 351. 50-624. 50) U/ml,Z =-5. 358,P = 0. 001]. Conclusion The degree of liver inflammation is positively correlated with that of liver fibrosis,while the serum level of IL-2 receptor increases with the increase in the degrees of liver inflammation and fibrosis,indicating that IL-2 receptor can reflect the degrees of liver inflammation and fibrosis to some extent.

     

    • FullText(HTML)
    • References(26)
  • [1] TERRAULT NA,BZOWEJ NH,CHANG KM,et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology,2016,63(1):261-283.
    [2] Polaris Observatory Collaborators. Global prevalence,treatment,and prevention of hepatitis B virus infection in 2016:A modelling study[J]. Lancet Gastroenterol Hepatol,2018,3(6):383-403.
    [3] CALVENTE CJ,TAMEDA M,JOHNSON CD,et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223[J]. J Clin Invest,2019,129(10):4091-4109.
    [4] CHANG ML,YANG SS. Metabolic signature of hepatic fibrosis:From individual pathways to systems biology[J]. Cells,2019,8(11):1423.
    [5] DENG YQ,ZHAO H,MA AL,et al. Selected cytokines serve as potential biomarkers for predicting liver inflammation and fibrosis in chronic hepatitis B patients with normal to mildly elevated aminotransferases[J]. Medicine(Baltimore),2015,94(45):e2003.
    [6] KARLMARK KR,WEISKIRCHEN R,ZIMMERMANN HW,et al.Hepatic recruitment of the inflammatory Gr1+monocyte subset upon liver injury promotes hepatic fibrosis[J]. Hepatology,2009,50(1):261-274.
    [7] MURAKAMI S. Soluble interleukin-2 receptor in cancer[J].Front Biosci,2004,9:3085-3090.
    [8] SUN Y,GU J,LIU R,et al. IL-2/IL-6 ratio correlates with liver function and recovery in acute liver injury patients[J].APMIS,2019,127(6):468-474.
    [9] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.
    [10] ORITO E,FUJIWARA K,KANIE H,et al. Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients[J]. World J Gastroenterol,2012,18(39):5570-5575.
    [11] CHEN YC,JENG WJ,CHU CM,et al. Decreasing levels of HBsAg predict HBs Ag seroclearance in patients with inactive chronic hepatitis B virus infection[J]. Clin Gastroenterol Hepatol,2012,10(3):297-302.
    [12] HSU A,LAI CL,YUEN MF. Update on the risk of hepatocellular carcinoma in chronic hepatitis B virus infection[J]. Curr Hepat Rep,2011,10(2):106-111.
    [13] XIONG M,LI J,YANG S,et al. Influence of gender and reproductive factors on liver fibrosis in patients with chronic hepatitis B infection[J]. Clin Transl Gastroenterol,2019,10(10):e00085.
    [14] CHIEN TL,WANG JH,KEE KM,et al. Factors predicting HBsAg seroclearance and alanine transaminase elevation in HBe Ag-negative hepatitis B virus-infected patients with persistently normal liver function[J]. PLo S One,2016,11(12):e0166543.
    [15] SETO WK,LAI CL,IP PP,et al. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B[J]. PLo S One,2012,7(2):e32622.
    [16] CHEN XL,HAN YD,WANG H. Relations of hepatic steatosis with liver functions,inflammations,glucolipid metabolism in chronic hepatitis B patients[J]. Eur Rev Med Pharmacol Sci,2018,22(17):5640-5646.
    [17] DUM,ZHANG S,XIAO L,et al. The relationship between serum bilirubin and elevated fibrotic indices among HBV carriers:A cross-sectional study of a Chinese population[J]. Int J Mol Sci,2016,17(12):e2057.
    [18] MILLONIG G,REIMANN FM,FRIEDRICH S,et al. Extrahepatic cholestasis increases liver stiffness(FibroScan)irrespective of fibrosis[J]. Hepatology,2008,48(5):1718-1723.
    [19] RAMACHANDRAN J,SAJITH KG,PRIYA S,et al. Serum cholinesterase is an excellent biomarker of liver cirrhosis[J]. Trop Gastroenterol,2014,35(1):15-20.
    [20] JIANG Q,MAO R,WU J,et al. Platelet activation during chronic hepatitis B infection exacerbates liver inflammation and promotes fibrosis[J]. J Med Virol,2019.[Online ahead of print]
    [21] SEIDLER S,ZIMMERMANN HW,WEISKIRCHEN R,et al. Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes[J]. BMC Gastroenterol,2012,12:38.
    [22] LAN T,CHANG L,WU L,et al. IL-6 plays a crucial role in HBV infection[J]. J Clin Transl Hepatol,2015,3(4):271-276.
    [23] WANG X,YAN Z,YE Q. Interleukin-6 gene polymorphisms and susceptibility to liver diseases:A meta-analysis[J].Medicine(Baltimore),2019,98(50):e18408.
    [24] YANG K,GUAN SH,ZHANG H,et al. Enhanced levels of interleukin-8 are associated with hepatitis B virus infection and resistance to interferon-alpha therapy[J]. Int J Mol Sci,2014,15(11):21286-21298.
    [25] SUH YG,KIM JK,BYUN JS,et al. CD11b(+)Gr1(+)bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice[J]. Hepatology,2012,56(5):1902-1912.
    [26] LIU Y,CHENG LS,WU SD,et al. IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection[J]. Clin Sci(Lond),2016,130(11):907-919.
    • Relative Articles

  • Relative Articles

    [1]Shaoxuan LUO, Ya LI, Feng XU. A case of hepatolenticular degeneration with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1119-1121. doi: 10.3969/j.issn.1001-5256.2022.05.028
    [2]Weiyuan FANG, Yi LU. Diagnosis and treatment of acute liver failure in children with Wilson's disease[J]. Journal of Clinical Hepatology, 2022, 38(2): 268-272. doi: 10.3969/j.issn.1001-5256.2022.02.004
    [3]Weiyuan FANG, Jianshe WANG. An excerpt of investigation and management of Wilson's disease: A practical guide from the British Association for the Study of the Liver (2022)[J]. Journal of Clinical Hepatology, 2022, 38(6): 1256-1257. doi: 10.3969/j.issn.1001-5256.2022.06.009
    [4]Wei ZHANG, Jian HUANG, Xiaojuan OU, Jidong JIA. Key points of AASLD practice guidance for the diagnosis and treatment of Wilson's disease (2022)[J]. Journal of Clinical Hepatology, 2022, 38(12): 2709-2711. doi: 10.3969/j.issn.1001-5256.2022.12.006
    [5]Zhou SiMin, Guo LiPing, Cai WangFeng, Zhou Lu, Wang BangMao. Latest advances in the treatment of hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2020, 36(1): 218-221. doi: 10.3969/j.issn.1001-5256.2020.01.052
    [6]Lu: Jia, Zhao Gang, Sun XueHua, Gao YueQiu. A case of hepatolenticular degeneration with neurological disorders as the prominent symptom[J]. Journal of Clinical Hepatology, 2019, 35(7): 1591-1593. doi: 10.3969/j.issn.1001-5256.2019.07.034
    [8]Huang DeLiang, Zhu ZhiBin, Yu Hong, Zhao Qi, Jiang JinYan, Chen YuanYuan, Dai Wei. Hepatolenticular degeneration with polycystic ovary syndrome: a case report[J]. Journal of Clinical Hepatology, 2018, 34(10): 2195-2196. doi: 10.3969/j.issn.1001-5256.2018.10.027
    [9]Li Xiang, Cai Jie, Xu YuWen, Yang Fen, Sun ALei, Weng YaLi. A case of hepatolenticular degeneration with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(9): 1967-1971. doi: 10.3969/j.issn.1001-5256.2018.09.027
    [10]Cheng Ran, Li YiJing, Fang Shu, Xu XiaoYuan, Wan Hua. A case of Wilson′s disease in adults with liver disease as the initial manifestation[J]. Journal of Clinical Hepatology, 2018, 34(3): 607-609. doi: 10.3969/j.issn.1001-5256.2018.03.035
    [11]Li ChunXia, Gong JingYu, Zhang MeiHong, Wang JianShe. Effect of pharmacotherapy on decompensated liver function in children with hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2017, 33(8): 1543-1547. doi: 10.3969/j.issn.1001-5256.2017.08.027
    [12]Fang Feng. Long-term treatment and follow-up management of children with hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2017, 33(10): 1936-1938. doi: 10.3969/j.issn.1001-5256.2017.10.017
    [13]Mao JiaXi, Zou You, Guo WenYuan. Clinical effect of liver transplantation in the treatment of hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2017, 33(10): 1977-1980. doi: 10.3969/j.issn.1001-5256.2017.10.026
    [14]Cui YuanYuan, Yang YiLiang, Wang ShaSha, Hua Rui. A case of hepatolenticular degeneration with mental disorder as initial symptomc[J]. Journal of Clinical Hepatology, 2016, 32(11): 2173-2174. doi: 10.3969/j.issn.1001-5256.2016.11.037
    [15]Yang Xu. Update on diagnosis and treatment of Wilson disease in China[J]. Journal of Clinical Hepatology, 2013, 29(12): 905-908. doi: 10.3969/j.issn.1001-5256.2013.12.008
    [16]Fan ZhenPing, Zhang HaiYan, Cai ShaoPing, Ji YingJie, Shi XueMin, Zhang WenJin. Diagnosis and treatment of hepatolenticular degeneration in adult patients with primary liver diseases[J]. Journal of Clinical Hepatology, 2013, 29(12): 940-942. doi: 10.3969/j.issn.1001-5256.2013.12.017
    [17]Lu Yi, Wang JianShe. Diagnosis of Wilson's disease in children[J]. Journal of Clinical Hepatology, 2012, 28(12): 907-910.
    [18]Wang ChaoXia, Zhang ChunYan. Clinical features and progress in diagnosis and treatment of hepatolenticular degeneration in children[J]. Journal of Clinical Hepatology, 2011, 27(7): 703-705.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(4)

    1. 赵贺，王冲，张文静，邵思论. 术前LSR、NLR及PLR检测评估结直肠癌预后的应用价值. 分子诊断与治疗杂志. 2022(02): 228-231+236 .
    2. 闫伟，戴雪娥，郉晓宇，陈韭铭. 肝癌患者TACE治疗前后血清免疫炎症相关因子的变化及意义. 中国肿瘤临床与康复. 2022(03): 269-273 .
    3. 邰新苗，张月怡，李继伟. 外周血中性粒细胞与淋巴细胞比值联合甲胎蛋白对HBV相关肝细胞癌的诊断价值. 现代消化及介入诊疗. 2021(03): 391-394 .
    4. 张小芳，刘志良，蔡勇，黄传生，罗庆丰. HIF-1α、MITF、CRP、NLR在乙型肝炎病毒感染相关性肝癌中的表达及其意义. 实用癌症杂志. 2021(07): 1084-1086 .

    Other cited types(6)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.0 %其他: 5.0 %其他: 0.3 %其他: 0.3 %China: 0.2 %China: 0.2 %India: 0.2 %India: 0.2 %Kathmandu: 0.2 %Kathmandu: 0.2 %Russian Federation: 0.2 %Russian Federation: 0.2 %三亚: 0.3 %三亚: 0.3 %上海: 4.3 %上海: 4.3 %东莞: 0.2 %东莞: 0.2 %中卫: 2.7 %中卫: 2.7 %乌鲁木齐: 0.2 %乌鲁木齐: 0.2 %九江: 0.3 %九江: 0.3 %佛山: 0.2 %佛山: 0.2 %保定: 0.3 %保定: 0.3 %北京: 20.1 %北京: 20.1 %北海: 0.2 %北海: 0.2 %匹兹堡: 0.2 %匹兹堡: 0.2 %南宁: 0.3 %南宁: 0.3 %南昌: 0.2 %南昌: 0.2 %台州: 0.2 %台州: 0.2 %吉安: 0.2 %吉安: 0.2 %吉林: 0.6 %吉林: 0.6 %吴忠: 0.2 %吴忠: 0.2 %哈尔滨: 0.2 %哈尔滨: 0.2 %唐山: 0.2 %唐山: 0.2 %商丘: 0.2 %商丘: 0.2 %天津: 0.6 %天津: 0.6 %太原: 0.2 %太原: 0.2 %宁波: 0.2 %宁波: 0.2 %安康: 0.2 %安康: 0.2 %张家口: 2.3 %张家口: 2.3 %张掖: 0.2 %张掖: 0.2 %徐州: 0.2 %徐州: 0.2 %成都: 0.5 %成都: 0.5 %扬州: 0.2 %扬州: 0.2 %新乡: 0.2 %新乡: 0.2 %日喀则: 0.2 %日喀则: 0.2 %昆明: 0.2 %昆明: 0.2 %昌吉: 0.2 %昌吉: 0.2 %朝阳: 0.2 %朝阳: 0.2 %杭州: 0.6 %杭州: 0.6 %武汉: 0.6 %武汉: 0.6 %沈阳: 0.5 %沈阳: 0.5 %济宁: 0.2 %济宁: 0.2 %海口: 0.3 %海口: 0.3 %深圳: 0.3 %深圳: 0.3 %清远: 0.2 %清远: 0.2 %漯河: 0.2 %漯河: 0.2 %漳州: 0.2 %漳州: 0.2 %烟台: 0.2 %烟台: 0.2 %盐城: 0.2 %盐城: 0.2 %盘锦: 0.2 %盘锦: 0.2 %福州: 0.5 %福州: 0.5 %绥化: 0.3 %绥化: 0.3 %芒廷维尤: 25.6 %芒廷维尤: 25.6 %莫斯科: 1.6 %莫斯科: 1.6 %菏泽: 0.2 %菏泽: 0.2 %萍乡: 0.3 %萍乡: 0.3 %蚌埠: 0.2 %蚌埠: 0.2 %衢州: 0.2 %衢州: 0.2 %西宁: 20.5 %西宁: 20.5 %西安: 0.2 %西安: 0.2 %贵阳: 0.2 %贵阳: 0.2 %赤峰: 0.2 %赤峰: 0.2 %达州: 0.2 %达州: 0.2 %运城: 0.2 %运城: 0.2 %郑州: 0.3 %郑州: 0.3 %酒泉: 0.2 %酒泉: 0.2 %重庆: 0.8 %重庆: 0.8 %金华: 0.2 %金华: 0.2 %银川: 0.5 %银川: 0.5 %长春: 1.1 %长春: 1.1 %长沙: 0.2 %长沙: 0.2 %长治: 0.2 %长治: 0.2 %阳泉: 0.2 %阳泉: 0.2 %黔东南: 0.2 %黔东南: 0.2 %齐齐哈尔: 0.2 %齐齐哈尔: 0.2 %龙岩: 0.3 %龙岩: 0.3 %其他其他ChinaIndiaKathmanduRussian Federation三亚上海东莞中卫乌鲁木齐九江佛山保定北京北海匹兹堡南宁南昌台州吉安吉林吴忠哈尔滨唐山商丘天津太原宁波安康张家口张掖徐州成都扬州新乡日喀则昆明昌吉朝阳杭州武汉沈阳济宁海口深圳清远漯河漳州烟台盐城盘锦福州绥化芒廷维尤莫斯科菏泽萍乡蚌埠衢州西宁西安贵阳赤峰达州运城郑州酒泉重庆金华银川长春长沙长治阳泉黔东南齐齐哈尔龙岩

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (4627) PDF downloads(96) Cited by(10)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2183]YesterdayPV[4802]TodayIP[396]TodayPV[694]Online[69]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return